Crossmark

Considerations for the use of inhaled antibiotics for <i>Pseudomonas aeruginosa</i> in people with cystic fibrosis receiving CFTR modulator therapy

Crossref DOI link: https://doi.org/10.1136/bmjresp-2023-002049

Published Online: 2024-05-03

Published Print: 2024-05

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Burgel, Pierre-Régis https://orcid.org/0000-0003-0903-9828
Ballmann, Manfred

Drevinek, Pavel

Heijerman, Harry

Jung, Andreas

Mainz, Jochen G

Peckham, Daniel

Plant, Barry J

Schwarz, Carsten

Taccetti, Giovanni

Smyth, Alan
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04509050 at ClinicalTrials.gov

Documents that mention this clinical trial

Considerations for the use of inhaled antibiotics for <i>Pseudomonas aeruginosa</i> in people with cystic fibrosis receiving CFTR modulator therapy
https://doi.org/10.1136/bmjresp-2023-002049
License Information

License valid from 2024-05-03